234 related articles for article (PubMed ID: 19059062)
41. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
42. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
43. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
44. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
Peppercorn J; Hamilton E; Marcom PK; Beskow L; Lyman GH
Cancer; 2013 Oct; 119(20):3703-9. PubMed ID: 23893861
[TBL] [Abstract][Full Text] [Related]
46. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
47. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
48. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
Flockhart D
Clin Adv Hematol Oncol; 2008 Jul; 6(7):493-4. PubMed ID: 18654115
[No Abstract] [Full Text] [Related]
49. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
50. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Schulz C; Heinemann V; Schalhorn A; Moosmann N; Zwingers T; Boeck S; Giessen C; Stemmler HJ
World J Gastroenterol; 2009 Oct; 15(40):5058-66. PubMed ID: 19859999
[TBL] [Abstract][Full Text] [Related]
51. Individualization of tamoxifen treatment for breast carcinoma.
Binkhorst L; van Gelder T; Mathijssen RH
Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
[TBL] [Abstract][Full Text] [Related]
52. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
53. CYP2D6 genotype and tamoxifen response.
Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
[No Abstract] [Full Text] [Related]
54. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
55. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.
Lyon E; Gastier Foster J; Palomaki GE; Pratt VM; Reynolds K; Sábato MF; Scott SA; Vitazka P;
Genet Med; 2012 Dec; 14(12):990-1000. PubMed ID: 22955113
[TBL] [Abstract][Full Text] [Related]
56. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenetics of breast cancer therapies.
Hertz DL; McLeod HL; Hoskins JM
Breast; 2009 Oct; 18 Suppl 3():S59-63. PubMed ID: 19914545
[TBL] [Abstract][Full Text] [Related]
58. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
59. Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
Pharmacogenomics; 2016 Dec; 17(18):1967-1969. PubMed ID: 27883289
[No Abstract] [Full Text] [Related]
60. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]